rated fatty acid (LC-PUFA) deficit that can occur during the early weeks of life of very preterm infants. 7 Therefore, 2 important aspects need to be considered with respect to parenteral lipids: first, a suitable dose to provide an adequate caloric intake, and second, a fatty acid composition that fulfills essential fatty acid (EFA) and, possibly, LC-PUFA requirements.
At the present time, only 2 emulsions are approved for use in the United States. These are long-chain triglyceride emulsions consisting of either 100% soybean oil or a 50:50 mixture of soybean and safflower oils. In contrast, numerous lipid emulsions of varying oil composition are available in Europe. These lipid emulsions, which contain various amounts of medium-chain triglycerides (MCTs), olive oil, and/or fish oil, have been used to modify the fatty acid composition of the lipid emulsions. They may provide some clinical benefits over the conventional pure soybean oil emulsions, 8 but it is not known how widely they are used.
If patients receive inadequate nutrition, whether because physicians are not knowledgeable of nutrition support or because of improper implementation, outcomes can be impaired. These concerns require a systematic assessment of nutrition planning and implementation in neonatal intensive care units (NICUs). It has been
Objective: To determine the types of parenteral lipid emulsions currently used for preterm infants, their mode of delivery, and the main disease conditions that are considered by neonatologists as contraindications. Design: National survey using a questionnaire. Setting: 155 neonatal departments in France. Results: 100 (65%) neonatal departments participated in the survey. The most widely used lipid emulsion was the 20% soybean oil/coconut oil-based emulsion (68% of the units), followed by the soybean oil-based emulsion (28.5%) and the soybean oil/olive oil-based emulsion (3.5%). Peripheral venous access was considered to be a possible route for the infusion of lipid emulsions in only 58 (63.7%) of the units. In 80%-90% of the units, sepsis, hemodynamic failure, thrombocytopenia, disseminated intravascular coagulation, and hyperbilirubinemia were considered to be relative or absolute contraindications, whereas only hemodynamic failure, disseminated intravascular coagulation, and to a lesser extent sepsis were most often perceived as absolute contraindications. Conclusions: Neonatologists are somewhat reluctant to use parenteral lipids when only peripheral venous access is available, despite the low osmolarity of the emulsions. This may impair, at least temporarily, the adequate supply of energy and/or essential fatty acids in infants who do not have central venous access. This study also shows a large heterogeneity of responses with regard to the contraindications for parenteral lipids. (Nutr Clin Pract. / Lapillonne et al 673 shown that development and implementation of evidence-based nutrition support practices in neonates led to improved nutrient intake and growth with reduced length of stay and related cost. 9 Surveys are a useful method for determining the knowledge base and therapeutic intentions of clinicians. Such surveys not only provide a reference standard but can help clinicians assess their practices with respect to published recommendations. Surprisingly, very few studies in the literature provide insight into neonatal parenteral lipid practices, and very little information is available concerning factors that significantly influence the prescription of parenteral lipids for preterm infants.
Parenteral Lipids in Neonatal ICUs
In view of the recognized clinical importance of parenteral lipids for preterm infants and the paucity of data available on the use of parenteral lipids in NICUs, we conducted a nationwide survey in France to determine (1) compliance with the recent European guidelines 10 with regard to the type of lipid emulsions used in NICUs and the timing and dose of parenteral lipids infused to very preterm infants and (2) the main conditions that can preclude or limit the use of parenteral lipids in preterm infants.
Methods
The survey used a questionnaire that was designed by the authors and then validated internally by the physicians of the Department of Neonatology and externally by the chairman of the Groupe d'Etudes en Néonatologie d'Ile de France (GEN-IF) (Ile-de-France Neonatology Study Group, Pr. Y. Aujard, Paris) and the executive committee of the Fédération Nationale des Pédiatres Néonatologistes (French Neonatal Society). 11 The main aim of the questionnaire was to determine the conditions under which lipid emulsions are prescribed for parenteral nutrition for premature infants. The first series of questions focused on the types of lipid emulsions currently used and their mode of delivery. The second series collected data on the date of initiation, initial dosage, rate of increment, and target parenteral lipid intake for premature infants with a birth weight ≤1500 g. The last series of questions related to the clinical conditions considered to be contraindications for the use of parenteral lipids.
An extensive list of neonatal departments in France and the French overseas territories was established by combining the lists of the French scientific societies involved in newborn care and those of the regional healthcare services. In France, the definition of the levels of care differs slightly from that used in the United States. 12 Level I units provide a basic level of newborn care for infants at low risk. Level II special care nurseries can look after infants who are moderately ill with problems that are expected to resolve rapidly and do not require mechanical ventilation. Unlike in the United States, there is no restriction on the basis of birth weight or gestational age. Some of these level II units (ie, level IIB) are able to provide continuous positive airway pressure and parenteral nutrition. Finally, level III NICUs are defined by their capacity to provide mechanical ventilation. These units are able to care for extremely LBW infants and have the facilities for high-frequency ventilation, inhaled nitric oxide, and surgery on site or at a nearby institution.
The questionnaire, accompanied by a cover letter and a reply envelope, was sent by post to the medical superintendents of all the French level III (n = 66) and level IIB (n = 89) neonatal units. Units not admitting premature infants were not asked to fill out the questionnaire. Reminders were sent twice to nonrespondents.
Statistical Analyses
The data were analyzed using Minitab 13.3 software (Minitab Inc, State College, PA). General frequency responses to all survey items were determined and used to test for associations among the categorical variables. Results from level II and III units were compared by Pearson χ 2 tests of independence. A P value of ≤0.05 was considered to be statistically significant. The study was approved by the GEN-IF and the Fédération Nationale des Pédiatres Néonatologistes.
Results

Response Rate
Among the 155 level IIB and level III neonatal departments, 100 (65%) responses were obtained, with a higher rate from level III (n = 56/66; 85%) than from level IIB units (n = 44/89; 50%) (P < .036). Nine level IIB units were excluded from the study because they did not prescribe parenteral lipids. The statistical analysis was performed on the remaining questionnaires from 91 units with a total of 2471 beds. Nine departments did not report their annual number of admissions, whereas the 82 others reported a total of 41,861 admissions per year (level III = 31, 197; IIb = 10, 667) . The mean ± standard deviation number of admissions per unit per year of infants born before 32 weeks of gestation was significantly higher in the level III than level IIB units (133 ± 64 vs 34 ± 29; P < .0001). The composition and frequency of use of each type of lipid emulsion are reported in Table 1 and Figure 1 , respectively. Use of a standard 10% emulsion was not reported in any of the units; only 20% emulsions were used ( Table 2 ). The most widely used 20% lipid emulsion was the soybean oil/coconut oil-based emulsion, which was used in 68% of the units; the soybean oil/olive oilbased emulsions and the soybean oil-based emulsions were used in 3.5% and 28.5% of the units, respectively. The type of lipid emulsion used differed significantly according to the level of the unit (P = .035) (Figure 1 ).
Compliance With Guidelines
Timing and dose of lipids infused to very preterm infants.
All units use parenteral lipids as part of parenteral nutrition for preterm infants. Compliance with European guidelines with regard to the day of starting nutrition and the maximum intake of lipids infused to infants with a birth weight of ≤1500 g is reported in Table 2 . The maximum intake was below the recommendations in 15% of the units and above the recommendations in 6% of the units. The initial dosage of lipids infused to infants with a birth weight ≤1500 g was 0.5 g/kg/d in 78% of the units and 1 g/kg/d in 22% of the units. The day of start, the maximum intake, and the initial dosage of lipids infused were similar in level IIB and III units.
Main Conditions That Can Preclude or Limit the Use of Parenteral Lipids for Preterm Infants
Venous access. Peripheral venous access, defined as the insertion of a needle or short catheter in a subcutaneous vein, was not considered to be a possible route for the infusion of lipid emulsions in 33 (36%) of the neonatal units, with a higher rate in level IIB than in level III units (56% vs 24%, respectively; P = .002).
A large proportion of neonatologists did not know the maximum osmolarity of parenteral nutrition that can be tolerated whatever the type of venous access (peripherally inserted central catheters, 23%; umbilical catheters, 26%; peripheral venous access, 26%) ( Table 3) . None of the units and 4.4% of the units considered that the osmolarity of the parenteral nutrition solution should be ≤800 mOsm/L when an umbilical catheter and a peripherally inserted central catheter are used, respectively, whereas 24% of the units declared that an osmolarity >800 mOsm/L can be used with peripheral venous access (Table 3) .
Disease conditions. The percentages of neonatal units considering suspected or proven sepsis, hemodynamic failure, thrombocytopenia, disseminated intravascular coagulation, or hyperbilirubinemia unrelated to acute infection as an absolute or relative contraindication for the use of parenteral lipid emulsions are reported in Table 4 . There were no significant differences between level IIB and level III units except in the case of hyperbilirubinemia unrelated to acute infection, which was more frequently rated as an absolute contraindication by level IIB units (13% vs 4%, P = .004).
In reply to an open question asking which other special disease conditions respondents considered to be a relative or an absolute contraindication, respiratory failure/hypoxemia/ pulmonary hypertension and hepatic dysfunction/cholestasis were each cited 3 times, hypertriglyceridemia and use of ibuprofen were each cited twice, and acidosis and exchange transfusion were each cited once.
Discussion
This study is the first of its type to assess the use of parenteral lipids as part of the nutrition therapy and strategies used in NICUs. This study provides new insights into the type of lipid emulsion used in a European country, the routes of delivery considered to be suitable for parenteral lipids, and the particular disease conditions perceived as contraindications by neonatologists.
Our study reveals that practices in the United States and Europe differ significantly with regard to the choice of the lipid emulsion for parenteral nutrition of newborns. Indeed, our survey shows that whereas only the 100% soybean oil and the 50:50 mixture of soybean and safflower oils are available in the United States, the most widely used type of lipid emulsion in France is the MCT/ soybean oil-based emulsion, the soybean oil emulsion being, in contrast, used in only one-quarter of the French neonatal units. Interestingly, both American and European guidelines are fairly imprecise with regard to the choice of the type of lipid emulsion, 10,13 the only recommendation being the use of 20% emulsions with no mention of the fatty acid composition. The 20% emulsions contain a lower ratio of phospholipid emulsifier/triglycerides than 10% lipid emulsions and allow more efficient triglyceride clearance, even at a higher triglyceride intake.
14 Our study shows that neonatologists are aware of the better tolerance of standard 20% emulsions because only these are currently prescribed.
With regard to fatty acid composition, there are some theoretical benefits to using MCT since their oxidation is rapid 15 and much less dependent on carnitine than that of long-chain triglycerides (LCTs) and since MCT/LCT emulsions lead to higher net fat oxidation, reduced liver derangement, improved white blood cell function, and fewer effects on pulmonary hemodynamics and gas exchange than LCT emulsions. 10 The use of the new olive oil/soybean oil-based lipid emulsion was recently studied in premature infants with encouraging results, 16 but our study shows that it is seldom used in French NICUs.
Although an intake of polyunsaturated fatty acids (PUFAs) is required to prevent any essential fatty acid deficiency, the adequacy of soybean lipid emulsions has been questioned because of its high linoleic acid content and its ω-6/ω-3 imbalance. There are some concerns that preterm infants, and especially the very preterm ones, may develop a severe docosahexaenoic acid (DHA) deficit during the first weeks of life. 7, 17 Interestingly, lowering the intake of PUFA precursors appears to enhance LC-PUFA status. 16, 18 The newly developed lipid emulsions containing fish oil may provide benefits over the other emulsions since they may increase DHA status; 19 reduce the severity of retinopathy of prematurity; 20 and decrease oxidative stress, 21 circulating phospholipid and cholesterol levels, 19 pulmonary hypertension, 22 and parenteral nutritioninduced cholestasis. 23 The use of these fish oil emulsions is currently under investigation in both the United States and Europe, and their safety should be assessed by adequately designed studies before their routine use.
Lipid emulsions were introduced into clinical practice not only to provide essential fatty acids but also to increase energy intake. 10, 24 Conversely, few data support the early initiation of parenteral administration of lipids as a means to improve growth or decrease long-term morbidity. 3, 25 One study investigated the efficacy of the early introduction of a high dose of parenteral lipids (ie, 3 g/ kg/d) and demonstrated good tolerance. 26 Our study shows that French neonatologists are somewhat reluctant to start parenteral lipids early, as about half of them do not start lipids during the first 3 days of life as recommended. A survey performed in the United States suggests that lipid emulsions are likely to be started earlier than in France since the mean amount of parenteral lipids on day 1 was 0.67-0.69 g/kg/d (range, 0-3), but it remains unclear when lipids are really started since some units did not start at day 1 of life and since no data after day 1 were reported in this article. 27 Although the use of central venous catheters (ie, peripherally inserted central catheters or umbilical catheters) is common and often required for the administration of intravenous nutrition, peripheral venous access can also be used in some cases. Concerns about the osmolarity of peripheral parenteral nutrition formulas usually relate to the risks of thrombophlebitis and extravascular suffusion. Our study shows that one-quarter of the neonatologists do not know what osmolarity of the parenteral nutrition solution can be tolerated according to the type of venous access. There is in fact no strong evidence in the literature indicating a clear cutoff osmolarity for central versus peripheral parenteral nutrition, and the experimental data obtained in animal models are not completely transferable to humans. 28 Parenteral nutrition with an osmolarity exceeding 800-900 mOsm/L has been widely thought to warrant use of a central line. 29, 30 However, it is possible to infuse parenteral nutrition with an osmolarity of around 1100 mOsm/L, 31 or even up to 1700 mOsm/L, through a peripheral venous line, at least as a short-term strategy, 32 without increasing the risk of thrombophlebitis. The guidelines for pediatric parenteral nutrition do not provide any recommendation for osmolarity when peripheral venous access is used.
10 This is probably due to the fact that, to our knowledge, no study has been performed on this topic in a pediatric population. In the absence of any data, it would be advisable to recommend an osmolarity similar to that recommended for adults (ie, peripheral parenteral nutrition should be administered for a limited period of time using solutions whose osmolarity does not exceed 850 mOsm/L). 29 Although lipid emulsions have a low osmolarity (~340 mOsm/L) and may have a protective effect on the endothelium, 33 one-third of the neonatal units did not consider peripheral venous access to be a possible route for the infusion of lipid emulsions.
Concerns have been expressed about the early administration of lipid emulsions because of potential adverse effects, including chronic lung disease, increases in pulmonary vascular resistance, impaired pulmonary gas exchange, bilirubin toxicity, sepsis, and free radical stress. The guidelines with regard to side effects or use in special disease conditions are therefore prudent, and it is recommended to avoid supplying lipid emulsions in high dosages or adjusting the delivery of intravenous lipids to plasma triglyceride concentrations. 10 In a recent study in the United States, a majority of neonatologists stated that lung disease, jaundice, pulmonary hypertension, and hyperglycemia were not contraindications to the initiation of parenteral lipids, 27 but the low response rate (23%) in this survey did not allow one to draw firm conclusions as to the special disease conditions that most neonatologists considered to be contraindications. 34 Contrary to the study of Hans et al, 27 we investigated the perceived contraindications of lipid emulsions not only for the initiation of lipids but also for their use throughout the time spent in the NICU. The results showed that in 80%-90% of the units, sepsis, hemodynamic failure, thrombocytopenia, disseminated intravascular coagulation, and hyperbilirubinemia were considered to be contraindications. However, hemodynamic failures, disseminated intravascular coagulation, and to a lesser extent sepsis were most often perceived as absolute contraindications.
There are concerns that lipid emulsions might support microbial growth, affect platelet numbers or function, and be involved in the development of cholestasis. 10 With regard to critically ill or infected patients, the European guidelines do not recommend stopping the lipid infusion but advise clinicians to monitor more closely the plasma triglyceride concentration and to adjust the dose in case of hyperlipidemia. 10 In case of severe unexplained thrombocytopenia, serum triglyceride concentrations should be monitored and parenteral lipid dosage could be reduced but not stopped in order to supply at least the minimal essential fatty acids requirements to maintain normal platelet function. With regard to severe acute respiratory failure with or without pulmonary hypertension and hyperbilirubinemia, the European guidelines acknowledge the lack of data in preterm infants. Studies aiming at assessing the complications and side effects of the available lipid emulsions for preterm infants are therefore warranted.
Finally, this study confirms the large heterogeneity among centers with regard to the nutrition management of neonates. 5, 9, 35 The level IIB centers, for example, were more prone to continue to use the traditional soybean oil-based emulsions and were less likely to use peripheral venous access as an alternative route for the infusion of lipid emulsions. However, the lower response rate of these units precludes drawing firm conclusion about their practice. In contrast, the 85% response rate of the level III units, where most of the very preterm infants are admitted, gives strength to our study and highlights the fact that it is difficult to implement new guidelines, recommendations, and products nationwide. 34 In conclusion, our survey shows that the type of lipid emulsion most widely used in French NICUs is the 20% soybean oil/coconut oil-based emulsion and not the traditional soybean oil emulsions. By providing data collected in a European country, our study also highlights the differences between the United States and Europe with regard to the choice of parenteral lipid in neonates, which raise numerous questions with regard to compliance with guidelines, interest of newly designed lipid emulsion, safety of use, and research needed in this field.
Furthermore, our study shows that neonatologists are somewhat reluctant to use parenteral lipids when only peripheral venous access is available, despite the low osmolarity of the emulsions. This may impair, at least temporarily, the adequate supply of energy or essential fatty acids in neonates who do not have central venous access. Finally, our study reveals a large heterogeneity of responses with regard to the contraindications for parenteral lipids, highlighting the fact that among the 3 macronutrients, parenterally administered fats are the least studied and least understood, especially in preterm infants.
